FARE - Food Allergy Research & Education Logo
About Us

10th Anniversary Celebration

For more than a decade, FARE has worked tirelessly to end suffering from food allergies, providing resources and support for patients as well as those who love and care for them.

FARE's 10th Anniversary Celebration

Today, FARE is THE trusted voice in the food allergy community as well as the national leader in food allergy research, education, and innovation. Because of FARE, the future for food allergy patients is bright with the promise of better treatments, better care, better access to care, and better overall quality of life. With the help of generous donors and passionate patient advocates, FARE has made significant strides in the food allergy space over the past decade. 

And for those reasons and many more, we celebrate 10 years of FARE!

FARE 10 Year Logo
$100 million raised

to help fund research, education, and advocacy programs.

50+ Clinical Network sites

that have made incredible progress with advancing knowledge and treatment for individuals and families impacted by food allergies.

14,000 patients

participating in the FARE Patient Registry, the largest national registry of food allergy patients.

10th Anniversary Co-Chairs

Adam Miller headshot

Adam Miller

FARE Board Member at Large; Managing Partner, Allerfund; Founder and former CEO, Cornerstone on Demand

Adam Miller is a Managing Partner at AllerFund, the first venture fund focused on food allergy companies. To support the food allergic community, Adam led the merger of Food Allergy & Anaphylaxis Network (FAAN) and Food Allergy Initiative (FAI) to create FARE, seeded Aimmune with Dave Bunning (which developed the first FDA-approved treatment for food allergies), and helped build the UCLA Food Allergy Program in Los Angeles.

Daniel Tasse Headshot

Daniel Tassé

CEO, DBV Technologies

Daniel Tassé serves as Chief Executive Officer and is a member of DBV’s Board of Directors, responsible for driving DBV’s mission to deliver meaningful solutions for patients with severe food allergy and other immunological diseases. An experienced pharmaceutical executive, Mr. Tassé brings his 30-year record of building, growing and leading global pharmaceutical businesses and extensive experience bringing innovative therapies to pediatric patients around the world. His deep regulatory and commercial experience have enabled him to bring ground-breaking therapies to patients and deliver strong returns to shareholders.

Supported By

We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site, or closing this box, you consent to our use of cookies.